Bevacizumab May Improve Chronic Bleeding from Gastrointestinal Lesions, With Hanny Al-Samkari, MD
Автор: HCPLive
Загружено: 2025-12-26
Просмотров: 25
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida, the HCPLive editorial team met with Hanny Al-Samkari, MD, the Peggy S. Blitz Endowed Chair in hematology and oncology at the Massachusetts General Hospital and associate professor of medicine at Harvard Medical School, to discuss his recent observational study investigating bevacizumab's effects on bleeding rates in patients with non-HHT etiologies including idiopathic angiodysplasia, esophagela varices, and von Willebrand disease.
“Not only did bevacizumab trigger a dramatic improvement in Hematologic Support Score, it reduced hospitalizations and emergency department visits, specifically due to vascular GI bleeding in these patients, by over 50% in the year after versus the year before starting bevacizumab," Al-Samkari told HCPLive. "And it did it pretty safely; most patients were able to deal with the side effects and stay out of the hospital with monthly to every 2-month low-dose bevacizumab infusions.”
Read more: https://www.hcplive.com/view/systemic...
#Hematology #Medicine #ASH2025
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
